Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.49 |
| ▸ | HRH1 | P35367 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7815467 | 0.81 | CYP1A2 (0.41) | SIGMAR1LMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL15908333 | 0.81 | SIGMAR1 (0.50) | SIGMAR1LMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL3939116 | 0.80 | ALDH1A1 (0.65) | SIGMAR1LMNACYP3A4CYP2D6CYP1A2 | |
| Hydrochloric Acid SCHEMBL14697614 | 0.79 | LMNA (0.50) | SIGMAR1LMNACYP3A4CYP2D6CYP1A2 | |
| Iodide SCHEMBL1775657 | 0.79 | ALDH1A1 (0.68) | SIGMAR1LMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL6970125 | 0.79 | ALDH1A1 (0.71) | SIGMAR1LMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL655612 | 0.79 | ALDH1A1 (0.71) | SIGMAR1LMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL655611 | 0.79 | ALDH1A1 (0.71) | SIGMAR1LMNACYP3A4CYP2D6CYP1A2 | |
| Prothixene SCHEMBL623020 | 0.77 | SLC6A2 (0.76) | SIGMAR1LMNACYP3A4CYP2D6CYP1A2 | |
| Prothixene SCHEMBL30557147 | 0.77 | SLC6A2 (0.76) | SIGMAR1LMNACYP3A4CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766873-B2 | Zuclopenthixol hydrochloride derivatives and Ebselen derivatives as ErbB2 inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2020-09-08 | — | — | US | disclosed |
| US-20190031639-A1 | ZUCLOPENTHIXOL HYDROCHLORIDE DERIVATIVES AND EBSELEN DERIVATIVES AS ERBB2 INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-01-31 | — | — | US | disclosed |
| EP-3402481-A1 | ZUCLOPENTHIXOL HYDROCHLORIDE DERIVATIVES AND EBSELEN DERIVATIVES AS ERBB2 INHIBITORS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017121755-A1 | ZUCLOPENTHIXOL HYDROCHLORIDE DERIVATIVES AND EBSELEN DERIVATIVES AS ERBB2 INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017121755-A1 | ZUCLOPENTHIXOL HYDROCHLORIDE DERIVATIVES AND EBSELEN DERIVATIVES AS ERBB2 INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-20 | — | — | WO | disclosed |
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
| US-5795888-A | ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 1998-08-18 | — | — | US | disclosed |
| US-5741791-A | ADMINISTERING COMPOUNDS WHICH INHIBIT SECRETION, CIRCULATION OR EFFECT OF INSULIN ANTAGONIZING PEPTIDES; CAN BE USED TO TREAT NON-INSULIN-DEPENDENT DIABETES MELLITUS | NOVO NORDISK A/S (DK) | 1998-04-21 | — | — | US | disclosed |
| US-5721254-A | ANTIINFLAMMATORY AGENTS; ANALGESICS | NOVO NORDISK A/S (DK) | 1998-02-24 | — | — | US | disclosed |
| US-5712292-A | N-substituted azaheterocyclic carboxylic acids and esters thereof | NOVO NORDISK A/S (DK) | 1998-01-27 | — | — | US | disclosed |
| US-5693649-A | ADMINISTERING TO TREAT NEUROGENIC INFLAMMATION, MIGRAINE OR DIABETIC NEUROPATHY | NOVO NORDISK A/S (DK) | 1997-12-02 | — | — | US | disclosed |
| US-5688788-A | ANTIINFLAMMATORY, ANALGESIC | NOVO NORDISK A/S (DK) | 1997-11-18 | — | — | US | disclosed |
| US-5668129-A | ANTIINFLAMMATORY AGENTS, ANALGESICS OR ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 1997-09-16 | — | — | US | disclosed |
| US-5595989-A | ANTIINFLAMMATORY AGENTS AND ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 1997-01-21 | — | — | US | disclosed |
| EP-0738262-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-23 | — | — | EP | disclosed |
| WO-1995018793-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031639-A1 | ZUCLOPENTHIXOL HYDROCHLORIDE DERIVATIVES AND EBSELEN DERIVATIVES AS ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | SIGMAR1 3662/4885LMNA 4093/4885CYP3A4 3407/4885 |
| US-10766873-B2 | Zuclopenthixol hydrochloride derivatives and Ebselen derivatives as ErbB2 inhibitors | ERBB2, ERBB3, EGFR | SIGMAR1 3662/4885LMNA 4093/4885CYP3A4 3407/4885 |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TFEB, FOXO3, FOXO1 | SIGMAR1 3567/4885LMNA 4094/4885CYP3A4 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.